oral, BP, selective OX1R GPCR antagonist

orally efficacious in panic attack models

from optimization of internal OX2R antagonist

ACS Med. Chem. Lett., May 5, 2020

Janssen R&D, San Diego, CA

JNJ-54717793 is a selective antagonist of the orexin-1 receptor intended for use in anxiety disorders, in contrast to dual orexin-1/2 inhibitors and orexin-2 inhibitors typically applied for sleep disorders. It’s…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.